Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

In Therapy-Related AML, p53 Mutations Already Exist

December 11, 2013
By Anna Azvolinsky
Article
Conference|American Society of Hematology Annual Meeting & Exposition (ASH)

In a study presented at the 2013 ASH meeting, researchers showed evidence that p53 mutations are already present in patients who develop treatment-related MDS and AML, results which could help identify high-risk patients prior to cytotoxic therapy.

Mutations in the tumor suppressor p53 are thought to arise in hematopoietic stem cells after exposure to chemotherapy and radiotherapy, causing therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), a cancer of the blood and bone marrow.

But in a surprising new finding that reverses this hypothesis, researchers now provide evidence that therapy-related AML actually arises due to the selection of pre-existing hematopoietic stem cells that harbor p53 mutations. Hematopoietic stem cells may acquire deleterious p53 mutations as a result of the normal aging process and are likely selected in the context of cytotoxic therapies, such as chemotherapy and radiation therapy.

The study results were presented at the plenary session of the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition, held in New Orleans.

“This new model explains many of the clinical features observed in therapy-induced AML,” said study presenter Terrence Neal Wong, MD, PhD, of Washington University in St. Louis, during his presentation. “This early loss of p53 may provide a mechanism for the resistance to chemotherapy and poor survival in these patients.”

AML is an aggressive malignancy of the bone marrow, characterized by a high relapse rate and resistance to chemotherapy agents, particularly for therapy-related AML. “Therapy-related myeloid malignancies are among the most feared long-term consequences of exposure to chemotherapy or radiation,” said Benjamin L. Ebert, MD, PhD, of the Brigham and Women’s Hospital and Harvard Medical School in Boston, who introduced the plenary presentation.

Therapy-related AML generally develops months or years after exposure to either radiation or chemotherapy. This type of blood disorder is characterized by a high incidence of p53 mutations compared with de novo AML, as well as a complex karyotype and poor overall survival.

The long-standing theory for the development of therapy-related AML is that the accumulation of mutations, including in key driver genes, as a result of exposure to cytotoxic therapy ultimately leads to clonal expansion and AML. But one observation was not consistent with this theory: Therapy-related AML does not have a particularly high mutation burden compared with de novo AML, which would be expected as a result of exposure to chemotherapy or radiotherapy.

Wong showed evidence that p53 mutations are present in the existing pool of hematopoietic stem cells prior to cytotoxic therapy exposure. This population of cells has a selective advantage and expands following therapy and acquires somatic mutations and karyotypic complexities that can ultimately lead to therapy-related AML.

Wong and colleagues expanded their initial analysis of 22 therapy-related AML and 49 de novo AML cases to include an additional 89 patients with therapy-related AML or MDS, finding that p53 mutations occurred in 31.5% of cases and was the only mutation that occurred at a higher frequency compared with de novo AML or MDS.

The study authors used next-generation whole genome sequencing that is able to detect rare cell subclones on paired bone marrow and skin specimens from therapy-related AML patients at diagnosis. They were able to show several cases where the driver p53 mutation was present prior to the emergence of other somatic driver mutations and other cytogenic abnormalities, and treatment exposure.

Using bone marrow chimeras, Wong showed that the heterozygous loss of p53 results in a competitive advantage following chemotherapy but not if the cells are not exposed to cytotoxic therapy. An early acquisition of a p53 mutation in a founding hematopoietic stem cell clone likely contributes to later AML development following cytotoxic therapy.

Mutations of p53 are particularly common in therapy-related diseases, including hematopoietic cancers. The gene plays a key role in response to cytotoxic-based therapies and an essential role in maintaining genomic stability.

This study result could help identify patients at high risk for therapy-related AML by monitoring patients and identifying hematopoietic stem cells with existing p53 mutations prior to cytotoxic therapy, said Ebert during his presentation. Additionally, those patients who have received cytotoxic therapy could be monitored for p53-mutated clones.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.


CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

Related Content

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.

Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer

Roman Fabbricatore
July 24th 2025
Article

A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Neoantigen Vaccines Are Leading to a Personalized Frontier in RCC Immunotherapy

Ashling Wahner
July 20th 2025
Article

David A. Braun, MD, PhD, discusses how neoantigen vaccines are redefining RCC treatment, with the potential to activate potent, lasting T-cell activity.


CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

CAR T-Cell Therapy to Target CAIX/CD70 Overexpression in ccRCC

Ashley Chan
July 19th 2025
Article

Researchers developed a CAR T-cell therapy to target CAIX/CD70 overexpression for patients with clear cell RCC.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.